KBU2046 |
| Catalog No.GC62119 |
KBU2046은 시험관 내에서 세포 운동성 및 세포 침윤의 경구, 고도로 선택적인 억제제입니다. KBU2046은 샤페론 이종복합체에 결합하고 운동성을 조절하는 클라이언트 단백질의 결합을 선택적으로 변경하며 기존 HSP90 억제제의 모든 특징이 없습니다. KBU2046은 암 전이를 억제하고 수명을 연장합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1143863-69-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
KBU2046 is an oral, highly selective inhibitor of cell motility and cell invasion in vitro. KBU2046 binds chaperone heterocomplexes, selectively alters binding of client proteins that regulate motility, and lacks all of the hallmarks of classical HSP90 inhibitors. KBU2046 inhibits cancer metastasis and prolongs life[1].
[1]. Xu L, et al. Precision therapeutic targeting of human cancer cell motility. Nat Commun. 2018 Jun 22;9(1):2454.
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *